CSTL

32.8601.63%
DJ

Derek J. Maetzold

Founder, CEO, President & Director

Mr. Derek J. Maetzold founded Castle Biosciences Incorporated in September 2007 and serves as its President, Chief Executive Officer and Director since September 2007. He serves as the Director at AltheaDx, Inc. since May 2021. He serves as the Director at Prelude Corporation (PreludeDx) since February 2, 2022. Mr. Maetzold served as the Vice President of Marketing and Sales at Encysive Pharmaceuticals Inc., (formerly, Texas Biotechnology Corp.,) from June 3, 2003 to May 2008. He served in the Cardiovascular and Allergy Global Marketing groups for Schering-Plough Corporation (Schering Corporation) from 1999 to June 2003, including Senior Director of Business Development, Director of Marketing and Allergy Business Unit and Director of Marketing Planning, Ezetimibe and Clarinex. Prior to Schering-Plough Corporation, Mr. Maetzold served as the Director/Associate Director of Marketing, North America at Amylin Pharmaceuticals from 1996 to 1998. From 1998 to 1999, he served as an Account Supervisor for Integrated Table of Contents Communications Corporation. He began his career at Sandoz Pharmaceuticals Corporation (now Novartis), where he held various sales and marketing positions from 1985 to 1996. He serves as a Director of the Ocular Melanoma Foundation. Mr. Maetzold holds a BS degree in Biology from George Mason University, he also completed coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside.

公司职务